Mersana Therapeutics (MRSN) Misses Q3 EPS by 137c

Mersana Therapeutics (NASDAQ: MRSN) reported Q3 EPS of ($1.51), $1.37 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $11 million versus the consensus estimate of $6.35 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15